Established in 2007 as a Centre of Excellence under the “Mission REACH” program of TIFAC-CORE, the Amrita Biomedical Engineering Centre (AMBE) is a state-of-the-art research facility committed to advancing knowledge and innovation in biomedical science and engineering. With a strong focus on developing affordable, point-of-care medical devices, the centre addresses critical healthcare challenges through practical, accessible solutions that can be deployed in real-world settings.
Over the years, AMBE has achieved significant milestones, including the development of paper-based analytical devices, low-cost insulin pumps, flexible energy storage systems, and lab-on-a-chip diagnostic platforms. Many of these technologies are designed specifically for use in resource-constrained environments, reflecting the centre’s mission to make quality healthcare more inclusive and accessible.
At the forefront of translational biomedical research, AMBE fosters close collaborations with both academia and industry, working to convert breakthrough research into impactful technologies. With innovation at its core and a deep commitment to societal benefit, the Centre continues to shape the future of affordable healthcare.
18 Crore External Funding
110+ Publications
9 Patents granted
The centre is dedicated to develop innovative point-of-care testing and critical care medical devices with a strong emphasis on affordability, accessibility, and real-world impact. Our research spans across multiple domains of healthcare technology, with a special focus on low-cost, high-performance diagnostics for underserved populations.
An automated and programmable immunoassay platform is being developed to translate the multiple steps involved in an electrochemical immunoassay for point-of-care quantification of thyroid hormones. The device consists of micromixers, micropump and microvalve array and is automated using microcontroller to meet different assay requirements.
The flexible, wearable symmetric microsupercapacitor operates at 1.2 V with a capacitance of 10 mF, showing stability over 15,000 cycles and endurance through 5,000 bending cycles.
A safe, flexible rechargeable alkaline thin-film battery (thickness < 1.0 mm) developed for wearables, featuring a high working potential of 1.8 V per cell and a capacity of 20 mAh, with durability exceeding 500 charge cycles.
The nonenzymatic glucose sensor strip developed overcomes the drawbacks of the commercially available counterparts by replacing the enzyme with metal oxide nanoparticles. In addition, a glucometer was also indigenously developed to test the glucose sensor. The product has successfully passed pre-compliance testing and is currently under clinical trials.
Low-cost drug delivery pump, which injects insulin into a diabetic patient at dynamically adjusted intervals, was developed to control blood sugar effectively. The insulin pump is a Type 4 infusion pump capable of delivering both basal and bolus doses of fast-acting insulin and was developed completely adhering to the IEC primary standard IEC 60601-2- 24
A lab-on-a-chip device that integrates impedimetric and colorimetric sensors for the detection of ESKAPE pathogens is being developed for the ultrasensitive detection and quantification of bacteria.
A stamp-sized paper strip enables a simultaneous colourimetric assay for liver function tests (LFT), quantifying SGOT, SGPT, ALP, bilirubin, and serum protein. It’s the first of its kind in India, and costs under ₹20. Designed for use at home, primary health centers, and clinics, the device requires only a finger-prick blood sample and delivers results in less than 20 minutes.
A Point-of-care detection device for fungal keratitis enables naked-eye identification of this potentially blinding fungal infection within 90 minutes, making it ideal for resource-limited settings and community screening.
Osteoporosis detection made easy, affordable, and early with a first-of-its-kind rapid protein-based screening tool (LFIA). This simple, user-friendly alternative to conventional DXA scans enables early detection before symptoms appear, all for less than ₹50.
Miniaturized, next-gen wearable nonenzymatic and enzymatic sensors for real-time monitoring of glucose, cholesterol, dopamine, pH, lactate, electrolytes, are being developed.
A simple and handheld battery-powered microhematocrit centrifuge that could directly convert the hematocrit into haemoglobin levels was developed to test anaemia in resource-limited settings.
